Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Funds Sought for Studies of Environment-Cancer Links

March 1, 2000
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 3
Volume 9
Issue 3

WASHINGTON-The Clinton Administration wants to sharply increase funding for studies to determine environmental causes of cancer, particularly of the breast and prostate. The President is asking Congress to provide $27 million in fiscal year 2001 to the Centers for Disease Control and Prevention (CDC) Environmental Health Lab, an increase of 56% over the current budget.

WASHINGTON—The Clinton Administration wants to sharply increase funding for studies to determine environmental causes of cancer, particularly of the breast and prostate. The President is asking Congress to provide $27 million in fiscal year 2001 to the Centers for Disease Control and Prevention (CDC) Environmental Health Lab, an increase of 56% over the current budget.

Some scientific evidence indicates that unknown environmental factors may increase the risk of breast and prostate cancer, the White House said. It noted that the CDC has reported links between the pesticide dieldrin and an increased risk of breast cancer and between polychlorinated biphenyls (PCBs) and an increased risk of non-Hodgkin’s lymphoma.

The funds would:

Double the level of assistance provided by CDC scientists to state and local public health officials investigating adverse health situations possibly linked to environmental exposure.

“As part of these interventions, the CDC will test the exposure of thousands of individuals to toxic substances to determine the cause of their illness,” the White House said.

Help identify areas where individuals are exposed to carcinogens and other toxic substances. The new funds would provide routine nationwide monitoring of more than 100 potentially toxic substances, including some 70 possible carcinogens.

Ensure that the Environmental Health Lab, working with state and local officials, can better address public health emergencies, such as pesticide contamination and chemical spills.

Articles in this issue

IL-13 Used to Deliver Bacterial Toxin to Brain Tumors in Mice
BAG-1 Overexpression Has a ‘Paradoxical’ Association With Improved Breast Cancer Survival
Rituximab/CHOP Combo Effective in Low-Grade NHL
3D CT-Guided Seminal Vesicle Biopsy for Staging
Elderly Patients Tolerate Breast Cancer Therapy
Coaxial Breast Biopsy Device Provides Diagnostic Specimens
3D Digital Camera Accurately Calculates Breast Shape, Volume
Thermoacoustic CT Under Development for Breast Imaging
Early Local Recurrence After Lumpectomy Predicts Metastasis
Panel Recommends Listing 9 Substances in Carcinogen Report
State of the Union on Youth Smoking ‘Clearly Not Good’
Low-Dose CT Screening Detects NSCLC: ELCAP Update
Mandatory HIV Testing of Newborns Not Routine: HHS
ASCO Launches Large-Scale Study on Quality of Cancer Care
Advocate Urges Greater Attention to Cancer Prevention Research
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
5 experts are featured in this series
3 panelists
Related Content
Advertisement

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial

Russ Conroy
December 23rd 2025
Article

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.


Achieving Accessible Cancer Care at Tennessee Oncology

Achieving Accessible Cancer Care at Tennessee Oncology

Ariana Pelosci
December 23rd 2025
Article

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Related Content
Advertisement

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.

Pimicotinib Earns Approval in China for Tenosynovial Giant Cell Tumors

Russ Conroy
December 23rd 2025
Article

Data from the phase 3 MANUEVER trial support the approval of pimicotinib for patients in China with symptomatic tenosynovial giant cell tumors.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO, and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.

Breast Cancer Data Affirm Aromatase Inhibitors as Optimal Endocrine Therapy

Andrea Eleazar, MHS
December 23rd 2025
Article

Exploratory data from a phase 3 study may help optimize adjuvant endocrine therapy choices in hormone receptor–positive, HER2-positive breast cancer.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.

Ceralasertib Combo Misses OS End Point in Advanced NSCLC Trial

Russ Conroy
December 23rd 2025
Article

Treatment with ceralasertib plus durvalumab was found to be well tolerated among patients enrolled on the phase 3 LATIFY trial.


Achieving Accessible Cancer Care at Tennessee Oncology

Achieving Accessible Cancer Care at Tennessee Oncology

Ariana Pelosci
December 23rd 2025
Article

How John G. Phillips, MD, MPH, and Tennessee Oncology are aiming to expand radiation oncology access in smaller communities across Tennessee.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.